Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to accumulation of toxic methylated sterols and depletion of ergosterol, disrupting membrane integrity and function.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Vaginal candidiasis,Oropharyngeal and esophageal candidiasis,Systemic candidiasis (including candidemia, disseminated candidiasis, and urinary tract infections),Cryptococcal meningitis,Prophylaxis of candidiasis in bone marrow transplant recipients,Off-label: Treatment of coccidioidomycosis, blastomycosis, histoplasmosis, and tinea infections
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
400 mg IV loading dose on day 1, then 200 mg IV once daily; for invasive candidiasis or cryptococcal meningitis, 800 mg IV loading dose then 400 mg IV once daily
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function. This long half-life allows once-daily dosing and achieves steady-state after 5-7 days.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Fluconazole is primarily metabolized by the liver via the cytochrome P450 system, specifically CYP2C9 and CYP3A4. It also inhibits CYP2C9, CYP2C19, and CYP3A4. Approximately 80% of a dose is excreted unchanged in urine; the remainder is metabolized to inactive metabolites.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal elimination of unchanged drug accounts for approximately 80% of the dose, with 11% as metabolites. Biliary/fecal excretion is minimal (<5%).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
11-12% bound to plasma proteins (primarily albumin).
Low protein binding; 0–11% bound, primarily to albumin.
Volume of distribution is approximately 0.7 L/kg (range 0.6-0.8 L/kg), indicating extensive distribution into total body water and tissues, including CSF, eyes, and urine.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Bioavailability of oral fluconazole is >90% (oral solution and tablets). IV administration (as in this product) provides 100% bioavailability.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Cr Cl >50 m L/min: no adjustment; Cr Cl ≤50 m L/min (not on dialysis): administer 50% of recommended dose; hemodialysis: one full dose after each dialysis session
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh A and B: no adjustment required; Child-Pugh C: limited data, use with caution and monitor closely
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Loading dose: 12 mg/kg IV (max 800 mg) on day 1; maintenance: 6 mg/kg IV once daily (max 400 mg); for invasive candidiasis or cryptococcal meningitis: loading 12 mg/kg IV (max 800 mg), then 6-12 mg/kg IV once daily (max 800 mg)
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
No specific dose adjustment; use based on renal function; age-related decline in renal function should be considered and Cr Cl calculated for dosing
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No FDA black box warning.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Hepatotoxicity: Monitor liver function tests; risk of hepatic necrosis and death.,QT prolongation: Risk of torsades de pointes, especially in patients with electrolyte abnormalities or concurrent QT-prolonging drugs.,Fetal risk: Use in pregnancy only if clearly needed, especially during first trimester (potential for teratogenicity).,Drug interactions: Increased risk of bleeding with warfarin; increased risk of toxicity from cyclosporine, phenytoin, and oral hypoglycemics; avoid coadministration with terfenadine, cisapride, and pimozide due to risk of QT prolongation.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to fluconazole or any excipient,Coadministration with terfenadine, cisapride, or pimozide (risk of serious cardiac arrhythmias),Coadministration with ergot alkaloids (risk of ergotism),Use in pregnancy (especially high-dose therapy) unless potential benefit outweighs risk
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No significant food interactions. However, avoid grapefruit and grapefruit juice as it may increase fluconazole levels. Maintain consistent intake of caffeine and alcohol as they may increase side effects like dizziness or liver strain.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
First trimester: Fluconazole is associated with a dose-dependent risk of congenital malformations, including craniofacial, skeletal, and cardiac defects, particularly with prolonged use of high doses (≥400 mg/day). Epidemiological data suggest a small increased risk of spontaneous abortion and major malformations with low-dose exposure. Second and third trimesters: Limited evidence of fetal toxicity; however, risks include preterm delivery and low birth weight with high-dose therapy. FDA Pregnancy Category D.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Fluconazole is excreted into breast milk in concentrations similar to maternal plasma. The milk-to-plasma (M/P) ratio is approximately 1.0. In full-term infants with normal renal function, exposure is low and considered compatible with breastfeeding. However, caution is advised in preterm infants or those with renal impairment. Monitor infant for diarrhea, jaundice, or feeding difficulties.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Increased plasma volume and enhanced renal clearance during pregnancy may require higher doses to maintain therapeutic levels, especially in the third trimester. For systemic infections, consider empiric dose increase by 50-100% or adjust based on therapeutic drug monitoring (target trough: 8-12 mg/L). Do not exceed 400 mg/day unless treating severe infections (e.g., coccidioidal meningitis) under specialist guidance.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Fluconazole in 0.9% Na Cl is an IV formulation; ensure compatibility before administration. May prolong QT interval, especially at high doses (≥400 mg/day); monitor ECG in patients with electrolyte disturbances or concurrent QT-prolonging drugs. Adjust dose in renal impairment (Cr Cl <50 m L/min: reduce by 50%). Maintain adequate hydration to prevent crystalluria. Do not mix with other medications in same IV line unless compatibility confirmed.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Take this medication exactly as prescribed by your doctor.,Inform your doctor if you have liver disease, kidney problems, or heart rhythm disorders.,Avoid driving or operating machinery until you know how this medication affects you.,Report signs of liver toxicity: dark urine, pale stools, yellowing of skin or eyes, persistent nausea.,Contact your doctor if you experience fast or irregular heartbeat, dizziness, or fainting.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Cobimetinib is primarily metabolized by CYP3A4, while fluconazole is a moderate inhibitor of CYP3A4. Coadministration may lead to increased cobimetinib exposure, potentially elevating the risk of adverse effects such as myopathy, hepatotoxicity, and cutaneous toxicities. Fluconazole serum concentration is unlikely to be significantly affected by cobimetinib."
"Propafenone, a class IC antiarrhythmic agent, is metabolized primarily by cytochrome P450 2D6 (CYP2D6) and to a lesser extent by CYP3A4 and CYP1A2. Fluconazole, a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4, can increase the plasma concentration of propafenone by inhibiting its CYP3A4-mediated metabolism. This can lead to enhanced antiarrhythmic effects and an increased risk of proarrhythmia, including ventricular tachycardia and other serious adverse events such as QT prolongation."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUCONAZOLE IN SODIUM CHLORIDE 0.9% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to accumulation of toxic methylated sterols and depletion of ergosterol, disrupting membrane integrity and function.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUCONAZOLE IN SODIUM CHLORIDE 0.9% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is: 400 mg IV loading dose on day 1, then 200 mg IV once daily; for invasive candidiasis or cryptococcal meningitis, 800 mg IV loading dose then 400 mg IV once daily. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUCONAZOLE IN SODIUM CHLORIDE 0.9% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is classified as Category A/B. First trimester: Fluconazole is associated with a dose-dependent risk of congenital malformations, including craniofacial, skeletal, and cardiac defects, particularly with prolonge. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.